Indumathy Varadarajan

Indumathy Varadarajan

Auto-generated profile, based on publicly available information

Indumathy Varadarajan

University of Virginia Comprehensive Cancer Center

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CFCiara L. Freeman
Ciara L. Freeman
RAReginald Atkins
Reginald Atkins
IVIndumathy Varadarajan
Indumathy Varadarajan
MMMeghan Menges
Meghan Menges
JEJeffrey Edelman
Jeffrey Edelman
FLFrederick L Locke
Frederick L Locke
Purpose: We investigated whether a dendritic cell (DC) vaccine transduced with an adenoviral vector encoded with full-length survivin (Ad-S), with mutations neutralizing its antiapoptotic function, could safely generate an immune response and deepen clinical responses when administered before and after autologous stem cell transplant (ASCT) for multiple myeloma. Patients and Methods: This phase I first-in-human trial (NCT02851056) evaluated the safety of DC:Ad-S in newly diagnosed multiple myeloma not having achieved complete response with induction, given 7 to 30 days prior to stem cell collection and 20 to 34 days after ASCT. Anti-survivin antibodies and CD4+ and CD8+ specific T cells were quantified. Results: A total of 14 patients were treated and 13 included in the primary efficacy analysis. No serious adverse events were attributed to DC:Ad-S vaccine. Detectable anti-survivin antibodies increased from baseline in 9 of 13 (69%) patients, and 11 of 13 (85%) mounted either a cellular or humoral immune response to survivin. Seven patients had an improved clinical response at day +90, all of whom had mounted an immune response, and 6 of 7 patients remain event-free at a median follow-up of 4.2 years. Estimated progression-free survival at 4 years is 71% (95% confidence interval, 41–88). Conclusions: Two doses of DC:Ad-S, one given immediately before and another after ASCT, were feasible and safe. A high frequency of vaccine-specific immune responses was seen in combination with durable clinical outcomes, supporting ongoing investigation into the potential of this approach. See related commentary by Dhodapkar, p. 4524

17 January 2026 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
SYSara Young
Sara Young
IVIndumathy Varadarajan
Indumathy Varadarajan
Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal complication associated with hematopoietic stem cell transplant (HSCT). Endothelial dysfunction and complement activation cause consumptive thrombocytopenia with intravascular hemolysis, resulting in end-organ damage, especially to the kidneys and lungs. There are no U.S. Food and Drug Administration (FDA)-approved agents for TA-TMA, although Eculizumab is the most commonly used agent to treat TA-TMA. Patients who do not respond to Eculizumab have a dismal prognosis, with reported mortality up to 80%. Narsoplimab, a mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor, has been shown to treat TA-TMA by inhibiting the lectin pathway of the complement cascade. We report the first adult case with successful management of eculizumab-refractory TA-TMA with Narsoplimab. Our patient received a matched unrelated donor (bone marrow) allogenic HSCT and subsequently developed multi-organ damage. He was refractory to numerous treatments, including eculizumab, steroids, rituximab, and plasma exchange. After developing diffuse Alveolar hemorrphage and renal failure, he was initiated on Narsoplimab and later achieved a complete hematological response and became transfusion independent. This case highlights the importance of early recognition of TA-TMA and the need to switch therapy to other complement inhibitors if resistance to Eculizumab is noted.

17 April 2026 in Blood Cancer Discovery
Verified
Journal Article
Open access
JDJustin M. Darrah
Justin M. Darrah
IVIndumathy Varadarajan
Indumathy Varadarajan
AMAmitkumar Mehta
Amitkumar Mehta
JSJennifer N Saultz
Jennifer N Saultz
MMMatthew S. McKinney
Matthew S. McKinney
RKReem Karmali
Reem Karmali
In relapsed/refractory large B-cell lymphoma (LBCL), chimeric antigen receptor (CAR)-natural killer (NK) cell therapies offer potential advantages over CAR-T-cell therapies, including off-the-shelf availability and scalable manufacturing. We performed a phase 2 study of single-dose TAK-007, a cryopreserved, cord blood-derived, off-the-shelf CD19 CAR-NK cell therapy, in 26 heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Adverse events were manageable, with limited grade 1–2 cytokine release syndrome (11.5%). Overall response rate with TAK-007 800 x106 CD19 CAR+ viable NK cells (n=14) was 60.9% (95% CI: 38.5–80.3). Median progression-free survival was 2.0 months (95% CI: 0.99–3.58) in LBCL (n=10) and 5.6 months (95% CI: 1.05–8.57) in indolent NHL (n=7) expansion cohorts. Deep molecular responses, including ctDNA-negative responses, were achieved. Not all TAK-007 products elicited clinical responses; single cell RNA-sequencing showed NK proliferating and NK-CD56dim cell enrichment in TAK-007 products eliciting/not eliciting responses, respectively, which could inform product selection.

28 September 2026 in International Journal of Cancer Care and Delivery
Verified
Journal Article
Open access
PDF file
IVIndumathy Varadarajan
Indumathy Varadarajan
KGKrishna Gandhi
Krishna Gandhi
From the 2026 National Summit on Hematologic Cancers

3 November 2026
Verified
Other
Open access
PDF file
JDJustin M. Darrah
Justin M. Darrah
IVIndumathy Varadarajan
Indumathy Varadarajan
AMAmitkumar Mehta
Amitkumar Mehta
JSJennifer N Saultz
Jennifer N Saultz
MMMatthew S. McKinney
Matthew S. McKinney
RKReem Karmali
Reem Karmali
Supplementary Table 3 shows the categorization of drug product lots based on clinical responses

3 November 2026
Verified
Other
Open access
PDF file
JDJustin M. Darrah
Justin M. Darrah
IVIndumathy Varadarajan
Indumathy Varadarajan
AMAmitkumar Mehta
Amitkumar Mehta
JSJennifer N Saultz
Jennifer N Saultz
MMMatthew S. McKinney
Matthew S. McKinney
RKReem Karmali
Reem Karmali
Supplementary Figure S3 shows B-cell counts over time in the pharmacodynamic population during dose escalation and dose expansion.